Shanghai Yingli Pharmaceutical Co. Ltd. has divulged new nitrogen-containing heterocyclic compounds acting as N-glycosylase/DNA lyase (OGG1) inhibitors potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Foshan Ionova Biotherapeutics Co. Ltd. has discovered new interleukin-17A (IL-17A) inhibitors potentially useful for the treatment of inflammatory disorders.

Riltide Medicines Co. Ltd. has identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors potentially useful for the treatment of autoimmune disease, rheumatic disease, cardiovascular, dermatological, renal, respiratory, neurological and inflammatory disorders, among others.

Astrazeneca AB has reported new antibody-drug conjugates (ADCs) comprising an antibody or antigen-binding fragment covalently linked to cytotoxic drug potentially useful for the treatment of cancer.

Avelos Therapeutics Inc. has patented new seleno-fused hetero ring DNA polymerase θ (POLθ) inhibitors potentially useful for the treatment of cancer.

A joint Ajax Therapeutics Inc. and Dana-Farber Cancer Institute Inc. patent divulges new JAK2 degradation inducers intended for use in the treatment of polycythemia vera, myeloid leukemia and essential thrombocythemia.

Pfizer Inc. has discovered new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity.

AN2 Therapeutics Inc. has synthesized boron heterocycle-containing compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors. They are designed for potential use in the treatment of cancer, hypophosphatasia, infections, metabolic, autoimmune and autoinflammatory diseases.

Gilead Sciences Inc. has identified new GTPase KRAS G12D mutant inhibitors and proteolysis targeting chimeras (PROTACS) comprising an E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS G12D mutant-targeting moiety potentially useful for the treatment of cancer.

Bristol Myers Squibb Co. (BMS) has disclosed new Ikaros family zinc finger protein 1 (IKZF1, Ikaros), IKZF2 (Helios), IKZF3 (Aiolos) and/or IKZF4 (Eos) degradation inducers potentially useful for the treatment of cancer.